First GLP-1 pills for weight loss go on sale in Australia

Direct Source Verification: This story is aggregated from The Sydney Morning Herald (smh.com.au). Full reporting rights and copyright belong to the primary publisher.
Australians can access the first GLP-1 pills for weight loss through private prescription from Friday, likely boosting sales of the popular drugs already used by more than half a million people here.

Australians can access the first GLP-1 pills for weight loss through private prescription from Friday, likely boosting sales of the popular drugs already used by more than half a million people here.

Glucagon-like peptide-1 receptor agonists, or GLP-1s, were previously only available through a weekly injection, while the new Wegovy and Foundayo pills are taken as daily oral tablets.

Wegovy has landed on shelves across Australia.Louise KennerleyChair of the RACGP Specific Interests Obesity Management group Dr Mark Mellor welcomed the new form of treatment.

“This gives patients more choice and it gives us as practitioners some flexibility with treating patients,” he said, with particular benefits for those who are concerned about using needles, or who see injectables as too serious of a treatment.

“We’ve got about 14 million people overall in Australia living with either overweight or obesity,” he said. “That’s a lot of people, and a proportion of them may want and need treatment to manage their condition.

“They may have tried multiple attempts at dieting and exercise, and have had no long-term success with that. And understandably, they’re now turning to treatment options beyond behaviour change.”

Use of GLP-1s is expected to surge in the coming years, with the drugs boasting powerful health effects including significant weight loss, improved blood glucose control and other metabolic health benefits.

However, experts have warned there is a lack of research into the wider effects of the medications, including the risk of malnutrition, which can cause serious health concerns but go unnoticed as symptoms of nutrient deficiency mimic the side effects of GLP-1s, including fatigue, nausea, diarrhoea and constipation. There are also concerns about the medications’ impact on people with eating disorders.

Professor Barbara Mintzes, a pharmaceutical policy expert at the University of Sydney’s School of Medicine and Health, said there was strong evidence of rapid weight gain when people come off the medication.

“There are high rates of people withdrawing early, and often people will end up discontinuing use partly because of the [gastrointestinal] side effects.”

Mintzes said GLP1s have not been tested for long-term use, which was problematic if people need to stay on the drugs for life to maintain the weight loss benefit.

“There are concerns about the potential nutritional deficiencies, older people having muscle wastage, pancreatitis [risk], and potentially an increased risk of thyroid cancer,” Mintzes said.

Mintzes said the clinical trials also included participants who were also receiving intensive nutritional and exercise interventions, which was not the message the public had been receiving.

GLP-1s work by curbing appetite, slowing digestion and promoting feelings of fullness.

The Wegovy pill, manufactured by Novo Nordisk, was approved by the TGA earlier this month.

It’s taken every morning on an empty stomach and stays stable at room temperature, unlike the injectable Wegovy, which requires refrigeration.

The new tablet’s pricing will vary by dose, ranging from about $260 per month for a 1.5mg tablet to $395 a month for 25mg. For patients on the lower doses, this works out at less than $10 a day.

The pill is cheaper than the injectable, which costs between $350 and $500 per month.

The new tablets are available on shelves from Friday, Novo Nordisk confirmed.

Competing manufacturer Lilly won approval for its rival pill Foundayo on Monday, promising availability “in the coming days”.

However, while doctors can prescribe the drug, stocks are yet to arrive in pharmacies.

Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist taken as a daily pill at any time, without food or water restrictions.

It is expected to cost between $250 and $370 per month, depending on the dose and the pharmacy.

Users need to be prescribed the pills by their doctor, which may also require an out-of-pocket cost.

The Australian government is facing growing pressure to add GLP-1s to the Pharmaceutical Benefits Scheme for weight loss.

Mellor said the high price point of the medicines means they remain out of reach for many with obesity, which disproportionately affects low and middle-income individuals.

“It’s a double whammy for certain people who are living with obesity [but] have the least access to treatment and the least means to afford treatment,” he said. “This is a real equity issue that we need to we need to overcome.”

Mintzes said GLP-1 pharmaceutical companies were getting around bans on direct-to-consumer advertising by a strategy known as “disease awareness advertising”.

Advertisements funded by Novo Nordisk and Lilly which do not name their products focus on the shame of being overweight or obese, which can discourage people from being active, and malign other weight loss lifestyle interventions, like healthy smoothies.

Mintzes said the reframing of obesity as a disease has meant it is now seen as purely a medical problem that has a pharmaceutical fix, sidelining the gold-standard holistic approach to weight management and the importance of a balanced diet and physical activity.

“Which is very consistent with a company having a pharmaceutical product to sell,” Mintzes said.

There are also concerns about people who are not overweight taking GLP-1s off label, who have not been involved in clinical trials and the risk benefit calculation is not known.

Start the day with a summary of the day’s most important and interesting stories, analysis and insights. Sign up for our Morning Edition newsletter.

You have reached your maximum number of saved items.

Remove items from your saved list to add more.

You've used all of your gift articles. 3 more will become available on the 1st of every month.

Original Source
https://www.smh.com.au/national/first-glp-1-pills-for-weight-loss-go-on-sale-in-australia-20261120-p61fub.html
Visit The Sydney Morning Herald ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health